Literature DB >> 4037243

Chronic transfusions in patients with sickle cell disease. Indications and problems.

S Piomelli.   

Abstract

The use of chronic transfusions in patients with sickle cell disease is now the common practice after a stroke has occurred, in order to prevent the highly probable recurrence. Clinical studies show that chronic transfusion prevents the recurrence of a stroke. Review of the natural history of sickle cell disease indicates, however, that the mortality and morbidity associated with hemoglobin SS disease are quite high. Use of chronic transfusion, given before the occurrence of stroke and other irreversible organ damage, can be considered as an alternative to the conservative management of sickle cell disease. Chronic transfusion has become practicable since the recent advances in chelation therapy have essentially eliminated the risk of secondary iron overload.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4037243

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  6 in total

1.  Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease.

Authors:  Zohreh Tatari-Calderone; Heather Gordish-Dressman; Ross Fasano; Michael Riggs; Catherine Fortier; Andrew D Campbell; Dominique Charron; Victor R Gordeuk; Naomi L C Luban; Stanislav Vukmanovic; Ryad Tamouza
Journal:  Hum Immunol       Date:  2015-10-22       Impact factor: 2.850

2.  Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease.

Authors:  Payal C Desai; Allison M Deal; Emily R Pfaff; Bahjat Qaqish; Leyna M Hebden; Yara A Park; Kenneth I Ataga
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

Review 3.  Genetics of transfusion recipient alloimmunization: can clues from susceptibility to autoimmunity pave the way?

Authors:  Zohreh Tatari-Calderone; Naomi L C Luban; Stanislav Vukmanovic
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

4.  Cardiovascular effects of hypertransfusion therapy in children with sickle cell anemia.

Authors:  L A Lester; P C Sodt; N Hutcheon; R A Arcilla
Journal:  Pediatr Cardiol       Date:  1990-07       Impact factor: 1.655

5.  The association of CD81 polymorphisms with alloimmunization in sickle cell disease.

Authors:  Zohreh Tatari-Calderone; Ryad Tamouza; Gama P Le Bouder; Ramita Dewan; Naomi L C Luban; Jacqueline Lasserre; Jacqueline Maury; François Lionnet; Rajagopal Krishnamoorthy; Robert Girot; Stanislav Vukmanovic
Journal:  Clin Dev Immunol       Date:  2013-05-22

6.  Interethnic diversity of the CD209 (rs4804803) gene promoter polymorphism in African but not American sickle cell disease.

Authors:  Jenelle A Noble; Kimberley C Duru; Aldiouma Guindo; Li Yi; Ikhide G Imumorin; Dapa A Diallo; Bolaji N Thomas
Journal:  PeerJ       Date:  2015-02-24       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.